C61
Conditions
Interventions
Group 1: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) patients routinely undergoing CT-based staging
Sponsors
Klinik und Poliklinik für Urologie und Kinderurologie, Universitätsklinikum Bonn
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Histologically and radiographically confirmed mHSPC Availability of Digital Imaging and Communications in Medicine (DICOM) data of an initial baseline CT scan for staging
Exclusion criteria
Exclusion criteria: Prior or concurrent treatment with Bisphosphonates or RANKL inhibitors (Denosumab) for mHSPC Poor quality of initial CT imaging precluding automated analysis by the AI tool Lack of traceability of SRE data in the patient file
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time from mHSPC diagnosis (date of staging scan/start of ADT) to the date of the first occurrence of an SRE (pathological fracture, spinal cord compression, need for bone radiotherapy/surgery) | — |
Secondary
| Measure | Time frame |
|---|---|
| Technical success rate of automated image processing by the AI tool Descriptive analysis of SRE incidence within the cohort over the follow-up period | — |
Countries
Germany
Contacts
Public ContactThomas Büttner
Klinik und Poliklinik für Urologie und Kinderurologie, Universitätsklinikum Bonn
Outcome results
None listed